US005447712A

United States Patent [19]

White et al.

[11] Patent Number: 5,447,712

[45] Date of Patent: Sep. 5, 1995

[54] **METHOD OF REDUCING CYCLOPHOSPHAMIDE INDUCED HEMORRHAGIC CYSTITIS**

[75] Inventors: **Randy D. White**, Crystal Lake; **Joseph A. Safron**, Grayslake; **Donovan E. Gordon**, Highland Park; **Deborah Rice**, Broadview, all of Ill.

[73] Assignee: **Free Radical Sciences**, Cambridge, Mass.

[21] Appl. No.: **164,069**

[22] Filed: **Dec. 9, 1993**

[51] **Int. Cl.**[6] **A61K 31/425**; A61K 49/00

[52] **U.S. Cl.** **514/110**; 514/369; 514/922; 514/974; 514/90

[58] **Field of Search** 514/369; 424/10

[56] **References Cited**

U.S. PATENT DOCUMENTS

2,712,202	7/1955	Hosler et al.	47/57.5
3,737,536	6/1973	Sagner et al.	424/246
3,755,578	8/1973	McFarland et al.	424/246
4,175,130	11/1979	Yamanaka et al.	424/270
4,335,210	7/1982	Meister et al.	435/113
4,338,315	7/1982	Paget et al.	424/246
4,398,026	8/1983	Takano	544/133
4,420,479	12/1983	Morwick et al.	424/246
4,434,158	2/1984	Meister	424/94
4,438,124	3/1984	Meister	424/270
4,563,471	1/1986	Satzinger et al.	514/369
4,647,453	3/1987	Meisner	424/54
4,647,571	3/1987	Meister	514/369
4,665,082	5/1987	Meister et al.	514/365
4,710,489	12/1987	Meister	514/18
4,752,618	7/1988	Mascioli et al.	514/549
4,775,675	10/1988	Gyorgydeak et al.	514/305
4,780,475	10/1988	Cerra et al.	514/408
4,784,685	11/1988	Meister	71/106
4,791,125	12/1988	Clark	514/369
4,798,835	1/1989	Krupp et al.	514/369
4,839,387	7/1989	Poli	514/19
4,868,114	9/1989	Nagasawa et al.	435/112
4,879,370	11/1989	Meister	530/331
4,963,577	10/1990	Schorlemmer et al.	514/369
5,002,953	3/1991	Hindley	514/275
5,028,627	7/1991	Kilbourn et al.	514/565
5,039,609	8/1991	Klein	435/68.1
5,053,387	10/1991	Alexander	514/2
5,055,446	10/1991	Alexander et al.	514/2
5,089,268	2/1992	Katz	424/450
5,095,027	3/1992	Goldberg et al.	514/369
5,158,883	10/1992	Griffith	435/240.2
5,208,249	5/1993	Rowe et al.	514/369
5,214,062	5/1993	Mark et al.	514/369

FOREIGN PATENT DOCUMENTS

0002978	12/1978	European Pat. Off. .
0257992	3/1988	European Pat. Off. .
0318330	5/1989	European Pat. Off. .
0327263A1	8/1989	European Pat. Off. .
0338459A2	10/1989	European Pat. Off. .
0373002	6/1990	European Pat. Off. .
0374390	6/1990	European Pat. Off. .
0415598A1	3/1991	European Pat. Off. .
2141765	3/1973	Germany .
47-8537	11/1972	Japan .
8403625	9/1984	WIPO .
91/14424	3/1991	WIPO .
93/11104	11/1991	WIPO .

OTHER PUBLICATIONS

Mitchell et al., Br. J. Cancer Suppl. VIII (1987 Jun.) pp. 96–104. Ref: 38.

Bounous, et al., *Immunoenhancing Property of Dietary Whey Protein in Mice, Role of Glutathoine,* Clinical Investigative Medicine, vol. 12, No. 4, pp. 154–161. 1989.

(List continued on next page.)

Primary Examiner—Raymond Henley, III
Assistant Examiner—Phyllis G. Spivack
Attorney, Agent, or Firm—Pennie & Edmonds

[57] **ABSTRACT**

A method is provided for reducing side effects caused by chemotherapeutic agents by administering to a patient in need thereof a therapeutically effective amount of a composition including L-2-oxothiazolidine-4-carboxylate specifically for reducing hemorrhagic cystitis in a patient at risk of same.

17 Claims, 4 Drawing Sheets